MedTrace Logo

Interleukin-1 Blockade in HF With Preserved EF

NCT02173548 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2018-06-19

Study results available
· View outcomes & findings →

Summary

* Heart Failure with Preserved Ejection Fraction (HFpEF) is a common form of heart failure
* Standard treatment for heart failure, show less than ideal results in HFpEF
* Evidence of systemic inflammation is common in all forms of heart failure, including HFpEF
* The main hypothesis of this study is that systemic inflammation contributes to heart failure symptoms and exercise limitations in patients with HFpEF
* The main objective is to treat patients with HFpEF and evidence of systemic inflammation with an anti-inflammatory drug targeting Interleukin-1 (or placebo) to determine effects on cardiovascular function

Conditions

  • Heart Failure With Normal Ejection Fraction

Interventions

DRUG

Anakinra

DRUG

Placebo

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Antonio Abbate, MD, PhD · Virginia Commonwealth University

  • Benjamin Van Tassell, PharmD · Virginia Commonwealth University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2017-04-11
Completion
2017-06-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02173548 on ClinicalTrials.gov